In brief: Psiron, pSivida, Meditech Research, Optiscan Imaging

By Ruth Beran
Thursday, 16 June, 2005

Greg Williams is Psiron's (ASC:PSX) new chief financial officer, a position he commenced on June 14. He has four years experience as CFO at AstraZeneca Australia as well as with smaller Australian technology companies.

pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has been granted its first Korean patent covering the electronic-based properties of biosilicon in the stimulaton of orthopaedic tissue repair and re-engineering where scaffolds are required to support new bone growth. The technology also has application for treatment of fractures that do not heal and in management and monitoring of reconstructive orthopaedic or implant surgery.

Meditech Research (ASX:MTR) has appointed Dr Julian Clark as non-executive director to replace Assoc Prof Tracey Brown who will step down to focus on her executive management role as research director. Clark is currently head of business development at the Walter and Eliza Hall Institute for Medical Research in Melbourne and director of his own management consultancy.

Optiscan Imaging (ASX:OIL) has received a Commercial Ready Grant worth a $1.9 million over the next three years for the development of a multiphoton microscope in the form of a miniaturised handheld probe.

Related News

TGA approves donanemab for treatment of early Alzheimer's

The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...

Ultra-processed foods linked to poor health, premature death

Evidence suggests a dose-response relationship between ultra-processed food consumption and...

Shorter radiotherapy course proves safe for prostate cancer

A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd